group
recent
identifi
gene
whose
peripher
blood
express
level
differenti
regul
acut
ischem
stroke
purpos
studi
determin
whether
earli
express
level
gene
predict
poststrok
blood
brain
barrier
bbb
disrupt
transcript
express
level
candid
gene
measur
peripher
blood
sampl
ischem
stroke
patient
emerg
depart
admiss
bbb
permeabl
assess
hour
follow
via
perfusionweight
imag
earli
heighten
express
level
gene
encod
protein
kinas
abind
scaffold
molecul
significantli
associ
bbb
disrupt
hour
posthospit
admiss
determin
predominantli
express
lymphocyt
peripher
blood
strongli
coexpress
gene
encod
adhes
molecul
integrin
alpha
subsequ
vitro
experi
reveal
heighten
express
primari
human
lymphocyt
associ
highli
adher
phenotyp
collect
result
suggest
express
level
may
clinic
util
prognost
biomark
poststrok
bbb
complic
like
elev
earli
patient
later
develop
poststrok
bbb
disrupt
due
presenc
invas
lymphocyt
popul
peripher
blood
inflammatori
state
persist
level
neurovascular
unit
follow
ischem
stroke
drive
delay
disrupt
blood
brain
barrier
bbb
within
around
infarct
region
heighten
activ
proteinas
disrupt
pericellular
junction
endothelium
allow
migrat
peripher
immun
cell
damag
brain
parenchyma
process
inher
compromis
integr
bbb
increas
risk
edema
hemorrhag
transform
natur
administr
thrombolyt
therapi
exacerb
risk
advers
event
worsen
outcom
patient
develop
complic
earli
identif
patient
risk
develop
bbb
complic
inform
acut
clinic
decis
regard
thrombolyt
intervent
ultim
improv
clinic
manag
patient
outcom
unfortun
diagnost
tool
present
avail
clinician
identifi
patient
risk
poststrok
bbb
complic
limit
current
perfusionweight
magnet
reson
imag
mri
use
gadoliniumdiethylen
triamin
pentaacet
acid
gddtpa
contrast
one
sensit
method
detect
earli
chang
bbb
permeabl
clinic
set
intact
bbb
larg
imperm
gddtpa
thu
hyperintens
postcontrast
enhanc
cerebrospin
fluid
csf
space
fluidattenu
invers
recoveri
flair
indic
bbb
disrupt
postcontrast
enhanc
label
hyperintens
acut
reperfus
injuri
earli
peripher
blood
express
associ
develop
poststrok
bbb
disrupt
order
determin
relationship
express
level
strokeassoci
candid
gene
poststrok
bbb
disrupt
first
recruit
modestli
size
discoveri
cohort
consist
acut
ischem
stroke
ai
patient
peripher
whole
blood
sampl
obtain
emerg
depart
admiss
transcript
profil
perform
via
microarray
bbb
permeabl
assess
via
level
harm
none
mild
moder
sever
perfusionweight
imag
hour
follow
fig
employ
biasreduc
logist
regress
use
forward
stepwis
variabl
select
determin
whether
earli
express
level
candid
gene
predict
develop
poststrok
sever
harm
median
time
symptom
onset
blood
draw
across
discoveri
cohort
subject
hour
term
clinic
demograph
characterist
patient
present
sever
harm
follow
significantli
older
display
higher
preval
dyslipidemia
rel
patient
present
lower
level
harm
tabl
furthermor
higher
proport
patient
present
sever
harm
receiv
thrombolyt
intervent
via
recombin
tissu
plasminogen
activ
rtpa
present
lower
level
harm
howev
differ
statist
signific
candid
gene
total
express
level
gene
encod
protein
kinas
pka
bind
scaffold
molecul
known
kinas
anchor
protein
significantli
associ
develop
poststrok
sever
harm
control
age
dyslipidemia
rtpa
p
odd
ratio
confid
interv
fig
specif
elev
whole
blood
express
level
total
emerg
depart
admiss
associ
increas
degre
harm
hour
follow
fig
furthermor
earli
total
express
level
show
modest
abil
predict
poststrok
bbb
disrupt
demonstr
sensit
confid
interv
specif
confid
interv
develop
sever
harm
fig
exhibit
strong
coexpress
peripher
blood
follow
stroke
order
gain
insight
possibl
role
context
post
stroke
bbb
disrupt
next
perform
genomewid
correl
analysi
correl
coeffici
express
level
gene
detect
via
microarray
calcul
gene
rank
base
absolut
strength
relationship
express
level
theoriz
gene
strongli
coexpress
would
like
mechanist
relat
encod
cellular
adhes
molecul
known
integrin
alpha
gene
dataset
whose
express
level
significantli
correl
fig
exhibit
robust
posit
associ
scientif
report
fig
furthermor
like
earli
express
level
posit
associ
develop
poststrok
sever
harm
posthoc
logist
regress
analysi
control
age
dyslipidemia
rtpa
p
odd
ratio
confid
interv
due
establish
role
mediat
leukocyt
extravas
hypothes
may
function
involv
mediat
leukocyt
traffick
poststrok
establish
bioinformat
predict
splice
variant
express
peripher
immun
system
appear
invers
regul
well
establish
subject
altern
splice
howev
littl
known
express
splice
variant
peripher
immun
system
code
three
splice
variant
known
gener
function
scaffold
protein
vari
biolog
activ
within
context
pka
signal
addit
establish
splice
variant
may
also
code
mani
six
bioinformat
predic
altern
splice
transcript
order
determin
splice
variant
respons
coregulatori
relationship
observ
first
aim
identifi
splice
variant
express
peripher
immun
system
primer
specif
establish
predic
splice
variant
design
base
variantspecif
prime
site
fig
rtpcr
use
probe
presenc
express
peripher
whole
blood
sampl
obtain
two
stroke
patient
two
healthi
subject
pcr
product
detect
test
splice
variant
sampl
fig
provid
direct
evid
establish
previous
bioinformat
predict
splice
variant
express
peripher
immun
system
possibl
second
set
primer
use
valid
express
previous
predict
variant
supplementari
figur
identifi
establish
previous
predict
splice
variant
express
peripher
immun
system
express
level
splice
variant
measur
parallel
peripher
blood
ident
recruit
independ
valid
cohort
ai
patient
use
qrtpcr
tabl
second
cohort
patient
earli
express
level
exhibit
signific
posit
correl
express
level
fig
interestingli
previous
predict
splice
variant
display
invers
relat
express
level
regard
fig
h
well
establish
splice
variant
supplementari
figur
data
suggest
strong
posit
relationship
express
observ
first
cohort
patient
primarili
driven
feasibl
due
fact
previous
predict
splice
variant
appear
express
much
lower
level
establish
splice
variant
indic
higher
ct
valu
qrtpcr
data
shown
product
significantli
less
pcr
product
standard
rtpcr
use
primer
design
coamplif
supplementari
figur
interestingli
encod
scaffold
protein
abil
bind
pka
remain
splice
variant
predict
undergo
nonsens
mediat
decay
gener
scaffold
protein
lack
pka
bind
domain
supplementari
figur
collect
data
valid
relationship
observ
discoveri
cohort
suggest
dynam
regul
pkabind
nonpkabind
variant
thu
ratio
express
level
splice
variant
may
diagnost
robust
express
level
total
alon
pkabind
isoform
highli
express
lymphocyt
peripher
blood
gain
insight
possibl
function
role
context
poststrok
bbb
disrupt
next
look
determin
cellular
sourc
peripher
immun
system
qrtpcr
use
measur
express
level
splice
variant
rna
extract
isol
leukocyt
subpopul
obtain
peripher
blood
three
healthi
donor
use
immunomagnet
neg
select
express
level
pkabind
isoform
appear
significantli
higher
cell
lymphoid
origin
fig
lead
us
hypothes
level
may
serv
marker
poststrok
lymphocyt
traffick
specif
order
test
hypothesi
may
marker
lymphocyt
extravas
specif
way
adhes
qrtpcr
use
measur
transcript
level
splice
variant
primari
human
lymphocyt
exhibit
strong
abil
adher
cultur
surfac
coat
matrix
abund
ligand
lymphocyt
isol
peripher
blood
three
healthi
donor
expand
hour
yield
healthi
activ
prolifer
lymphocyt
fig
lymphocyt
plate
cultur
dish
coat
matrix
compos
collagen
laminin
fibronectin
serumfre
condit
allow
minut
adher
nonadher
lymphocyt
collect
cultur
supernat
fig
adher
lymphocyt
separ
harvest
fig
viabil
cell
fraction
assess
via
trypan
blue
rna
extract
gene
express
analysi
cell
viabil
greater
popul
case
everi
donor
express
level
pkabind
variant
significantli
higher
lymphocyt
adher
fraction
nonadher
fraction
fig
collect
data
suggest
express
marker
lymphocyt
adhes
like
elev
patient
later
develop
poststrok
bbb
disrupt
result
presenc
invas
lymphocyt
popul
peripher
blood
object
studi
determin
whether
earli
express
level
candid
gene
previous
establish
differenti
regul
ai
could
use
identifi
patient
high
risk
poststrok
bbb
disrupt
result
suggest
elev
express
level
earli
acut
phase
care
may
predic
develop
bbbdisrupt
day
follow
injuri
furthermor
show
evid
express
may
elev
patient
later
develop
poststrok
bbb
disrupt
result
presenc
invas
lymphocyt
popul
peripher
circul
wide
express
scaffold
protein
whose
primari
cellular
function
spatial
regul
cyclic
adenosin
monophosph
camp
signal
via
cytoskelet
anchor
pka
altern
splice
result
multipl
isoform
function
divers
within
context
akinas
signal
gene
code
three
splice
variant
known
express
produc
function
protein
isoform
supplementari
figur
isoform
contain
conserv
pkabind
domain
distinct
tether
domain
target
motif
associ
differ
intracellular
local
uniqu
regard
contain
phosphodiesteras
pde
domain
function
domain
current
unclear
structur
similar
bacteri
rna
ligas
led
hypothesi
may
rna
ligas
activ
studi
shown
amp
bind
abil
led
suggest
serv
amp
sensor
addit
splice
variant
known
code
protein
nation
center
biotechnolog
inform
ncbi
eukaryot
genom
pipelin
previous
predict
gene
may
also
code
mani
six
addit
splice
variant
sequenc
previous
predic
splice
variant
suggest
would
target
nonsens
mediat
decay
other
would
gener
protein
isoform
contain
pde
domain
lack
pka
bind
domain
supplementari
figur
wide
studi
skelet
muscl
cardiac
tissu
brain
littl
known
physiolog
role
peripher
immun
system
order
gain
insight
possibl
function
leukocyt
context
poststrok
bbb
disrupt
aim
establish
splice
variant
express
peripher
immun
system
follow
stroke
determin
cell
popul
express
well
identifi
molecul
exhibit
pattern
coregul
result
provid
evid
previous
establish
protein
code
splice
variant
well
previous
predict
splice
variant
express
peripher
immun
system
result
suggest
pkabind
isoform
predominantli
express
cell
lymphoid
origin
express
level
highli
correl
cell
adhes
molecul
known
interact
variou
extracellular
matrix
protein
includ
laminin
collagen
fibronectin
recent
shown
signal
via
camp
pka
upon
ligand
bind
thu
highli
plausibl
strong
relationship
observ
express
level
pkabind
splice
variant
express
level
exist
isoform
mediat
interact
pka
interestingli
elev
express
associ
lymphocyt
invas
inhibit
shown
limit
leukocyt
extravas
inflammatori
condit
sepsi
light
observ
inform
led
us
hypothes
pkabind
isoform
marker
lymphocyt
adhes
like
elev
patient
later
develop
poststrok
bbb
disrupt
result
presenc
invas
lymphocyt
popul
peripher
blood
result
vitro
experi
support
hypothesi
express
level
pkabind
isoform
along
express
level
elev
primari
lymphocyt
exhibit
strongli
adher
phenotyp
indic
invas
presenc
lymphocyt
popul
properti
peripher
immun
system
follow
stroke
could
contribut
disrupt
bbb
direct
indirect
mechan
process
cerebrovascular
lymphocyt
extravas
alon
inher
reduc
integr
bbb
heighten
accumul
lymphocyt
brain
parenchyma
increas
risk
bbb
disrupt
via
develop
adapt
immun
respons
direct
central
nervou
system
antigen
develop
respons
lead
lymphocytemedi
product
proinflammatori
chemokin
drive
increas
influx
innat
immun
cell
popul
neutrophil
monocyt
peripheri
central
nerviou
system
process
myeloid
immun
popul
produc
proteolyt
molecul
matrix
metalloproteinas
act
compromis
integr
bbb
expectedli
shown
multipl
studi
increas
lymphocyt
activ
poststok
lead
poor
prognosi
thu
result
suggest
molecul
could
potenti
target
therapeut
limit
lymphocytemedi
poststrok
injuri
exacerb
addit
find
suggest
may
clinic
use
biomark
earli
identif
patient
heighten
risk
poststrok
bbb
disrupt
allow
clinician
make
inform
decis
regard
administr
thrombolyt
therapi
ultim
improv
clinic
manag
result
sever
prior
studi
look
identifi
blood
biomark
predic
develop
poststrok
bbb
disrupt
wide
investig
consid
promis
potenti
biomark
calcium
bind
protein
b
multipl
studi
observ
earli
elev
plasma
level
ai
patient
later
develop
bbb
disrupt
howev
exhibit
modest
level
diagnost
robust
largest
clinic
studi
perform
date
evalu
abil
identifi
patient
risk
poststrok
bbb
disrupt
abl
sensit
specif
studi
report
albeit
limit
sampl
size
earli
transcript
level
exhibit
abil
predict
poststrok
bbb
disrupt
level
diagnost
perform
exceed
report
regard
major
previous
propos
biomark
find
make
candid
clinic
evalu
regard
biomark
use
addit
provid
insight
role
leukocyt
context
stroke
studi
gener
novel
data
regard
genom
regul
studi
first
provid
substanti
evid
six
splice
variant
bioinformat
predict
ncbi
eukaryot
genom
pipelin
express
natur
variant
predict
undergo
nonsens
mediat
decay
base
presenc
stop
codon
nucleotid
upstream
first
exonexon
figur
express
splice
variant
primari
leukocyt
popul
isol
peripher
blood
ah
transcript
express
level
splice
variant
primari
leukocyt
popul
isol
peripher
blood
two
male
one
femal
heathi
donor
measur
qrtpcr
splice
variant
translat
produc
pkabind
isoform
highlight
express
level
present
fold
differ
rel
popul
lowest
express
statist
compar
use
oneway
anova
junction
sequenc
remain
previous
predic
splice
variant
suggest
capac
code
protein
protein
isoform
would
gener
splice
variant
would
highli
homolog
howev
lack
presenc
pka
bind
domain
suggest
like
protein
isoform
exist
natur
lack
akinas
bind
abil
possibl
isoform
could
act
decoy
protein
occupi
anchor
site
inhibit
scaffold
akinas
altern
three
four
potenti
protein
isoform
predict
contain
untrunc
pde
domain
predomin
featur
also
plausibl
biolog
function
directli
infer
pde
domain
futur
studi
provid
insight
regard
role
pde
domain
function
previous
predic
splice
variant
may
becom
clear
result
impli
previous
predict
splice
variant
express
much
lower
level
peripher
immun
system
establish
splice
variant
code
pkabind
protein
isoform
howev
dynam
intravari
regul
observ
suggest
biolog
signific
expectedli
due
seemingli
oppos
biolog
function
within
context
akinas
signal
observ
invers
regul
express
level
previous
predict
splice
variant
establish
splice
variant
code
pkabind
protein
isoform
thu
altern
splice
may
play
much
larger
role
regul
camp
signal
previous
anticip
due
preliminari
natur
studi
import
note
without
limit
sampl
size
studi
larg
enough
draw
definit
conclus
regard
potenti
use
clinic
biomark
predict
poststrok
bbb
complic
howev
feel
result
preliminari
analysi
promis
investig
prognost
valu
larger
clinic
cohort
warrant
term
understand
mechanist
role
peripher
immun
system
regard
stroke
pathophysiolog
much
analysi
studi
associ
natur
perform
level
transcript
biolog
mechan
propos
base
associ
observ
studi
valid
futur
preclin
work
take
direct
experiment
approach
potenti
via
genet
manipul
invivo
furthermor
assumpt
associ
whole
blood
level
poststrok
bbb
disrupt
driven
lymphocytedepend
mechan
base
observ
lymphocytespecif
express
isol
leukocyt
subpopul
howev
analysi
restrict
limit
number
healthi
individu
survey
three
predomin
subpopul
leukocyt
thu
futur
work
may
want
address
possibl
nonlymphoid
sourc
may
contribut
whole
blood
elev
express
level
observ
poststrok
bbb
disrupt
despit
aforement
limit
feel
work
provid
compel
evid
peripher
immun
system
play
role
poststrok
bbb
patholog
feel
result
provid
valuabl
foundat
knowledg
allow
indepth
explor
clinic
biomark
therapeut
target
regard
poststrok
bbb
disrupt
collect
result
suggest
earli
express
level
peripher
immun
system
predict
develop
bbb
disrupt
day
follow
ischem
stroke
furthermor
find
suggest
marker
highli
adher
lymphocyt
phenotyp
may
elev
patient
later
develop
poststrok
bbb
disrupt
result
presenc
invas
lymphocyt
phenotyp
peripher
blood
thu
may
clinic
use
biomark
identif
patient
heighten
risk
develop
poststrok
bbb
disrupt
work
yield
novel
insight
regard
biolog
context
peripher
immun
system
provid
foundat
studi
regard
role
stroke
patholog
discoveri
cohort
patient
discoveri
cohort
ai
patient
recruit
suburban
hospit
bethesda
md
ai
patient
display
definit
radiograph
evid
vascular
ischem
patholog
mri
accord
establish
criteria
diagnosi
acut
ischem
cerebrovascular
syndrom
aic
diagnos
confirm
experienc
neurologist
prospect
subject
exclud
display
radiograph
evid
bbb
disrupt
emerg
depart
admiss
report
prior
hospit
within
day
year
age
admit
hour
postsymptom
onset
type
cerebr
infarct
classifi
via
four
categori
describ
bamford
et
al
base
sole
radiograph
evid
follow
anterior
circul
infarct
restrict
cortic
involv
partial
anterior
cerebr
infarct
larg
anterior
circul
infarct
cortic
subcort
involv
total
anterior
cerebr
infarct
small
perfor
arteri
infarct
lacunar
cerebr
infarct
vertebrobasilar
territori
infarct
posterior
cerebr
infarct
time
symptom
onset
determin
time
patient
last
known
free
ai
symptom
injuri
sever
determin
accord
nation
institut
health
stroke
scale
nihss
time
blood
draw
demograph
inform
collect
either
subject
signific
train
clinician
procedur
approv
institut
review
board
nation
institut
neurolog
disordersn
institut
age
nation
institut
health
suburban
hospit
experi
perform
accord
relev
guidelin
regul
inform
consent
obtain
subject
author
repres
prior
studi
procedur
morgantown
west
virginia
ai
patient
display
definit
radiograph
evid
vascular
ischem
patholog
either
comput
tomographi
ct
mri
accord
aic
diagnost
criteria
util
discoveri
cohort
recruit
patient
exclus
stroke
subtyp
classif
assess
injuri
sever
collect
demograph
inform
perform
ident
manner
regard
discoveri
cohort
procedur
approv
institut
review
board
west
virginia
univers
rubi
memori
hospit
experi
perform
accord
relev
guidelin
regul
inform
consent
obtain
subject
author
repres
prior
studi
procedur
magnet
reson
imag
assess
harm
mri
perform
discoveri
cohort
patient
use
clinic
magnet
reson
system
emerg
depart
admiss
hour
followup
standard
protocol
includ
diffusionweight
imag
gradientrecal
echo
flair
perfusionweight
imag
perfusionweight
imag
obtain
use
bolu
passag
gddtpa
mmolkg
flair
imag
assess
locat
level
harm
previous
describ
harm
posit
identifi
postcontrast
appear
csf
hyperintens
sulci
ventricl
fig
level
harm
classifi
base
follow
criteria
hyperintens
none
punctat
region
hyperintens
mild
continu
region
hyperintens
consecut
imag
moder
continu
region
hyperintens
consecut
imag
sever
imag
review
sequenti
expert
reader
blind
clinic
inform
blood
collect
rna
extract
peripher
blood
sampl
collect
via
paxgen
rna
tube
qiagen
valencia
ca
store
rna
extract
rna
extract
via
preanalytix
paxgen
blood
rna
kit
qiagen
autom
use
qiacub
system
qiagen
quantiti
puriti
isol
rna
determin
via
spectrophotometri
nanodrop
thermo
scientif
waltham
qualiti
rna
confirm
chip
capillari
electrophoresi
agil
bioanalyz
agil
technolog
santa
clara
ca
microarray
rna
amplifi
biotinyl
use
totalprep
rna
amplif
kit
appli
biosystem
grand
island
ny
sampl
hybrid
express
bead
chip
illumina
san
diego
ca
scan
use
illumina
beadstat
raw
probe
intens
background
subtract
quantil
normal
summar
gene
level
total
gene
express
use
illumina
genomestudio
sampl
label
hybrid
scan
perform
per
standard
illumina
protocol
mrna
express
valu
present
normal
mean
probe
intens
raw
data
avail
via
ncbi
gene
express
omnibu
geo
access
genomewid
correl
analysi
correl
coeffici
express
level
gene
identifi
predict
sever
harm
remain
gene
detect
via
microarray
calcul
gene
rank
base
absolut
strength
relationship
express
level
scientif
report
harmassoci
gene
statist
signific
relationship
evalu
via
twotail
critic
test
bonferroni
correct
account
multipl
comparison
rtpcr
cdna
synthes
use
appli
biosystem
high
capac
revers
transcript
kit
quantit
pcr
target
sequenc
amplifi
ng
cdna
input
use
custom
probe
set
design
use
ncbi
primer
design
tool
detect
via
sybr
green
powersybr
thermofish
rotorgeneq
qiagen
raw
amplif
plot
background
correct
ct
valu
gener
via
rotorgeneq
softwar
packag
reaction
perform
triplic
transcript
ppib
actb
amplifi
low
variabl
refer
normal
perform
use
normagen
datadriven
normal
algorithm
express
valu
present
fold
differ
rel
control
case
groupwis
comparis
fold
valu
rel
lowest
express
correl
analysi
nonquantit
pcr
applic
ng
templat
amplifi
use
reddymix
complet
master
mix
thermo
scientif
product
visual
via
ethidium
bromid
follow
agaros
gel
electrophoresi
primer
sequenc
thermocycl
condit
list
supplementari
tabl
isol
leukocyt
subpopul
blood
collect
healthi
donor
via
k
edta
vacutain
leukocyt
isol
via
immunomagnet
neg
select
easysep
direct
stemcel
technolog
vancouv
ca
neutrophil
total
lymphocyt
monocyt
isol
ml
edtatr
blood
per
manufactur
instruct
isol
cell
rins
pb
lyse
qiagen
buffer
rlt
contain
betamercaptoethanol
flash
frozen
liquid
nitrogen
store
rna
extract
primari
lymphocyt
cultur
adhes
assay
cell
cultur
perform
use
asept
techniqu
standard
mammalian
cultur
condit
isol
primari
lymphocyt
ml
whole
peripher
blood
collect
via
edta
vacutain
peripher
blood
mononuclear
cell
isol
via
densiti
gradient
centrifug
two
round
differenti
plate
perform
separ
monocyt
lymphocyt
lymphocyt
expand
hour
growth
media
compris
life
technolog
grand
island
ny
contain
autolog
human
serum
betamercaptoethanol
gibco
grand
island
ny
phytohaemagglutinin
pha
gibco
hepe
gibco
adhes
assay
expand
lymphocyt
suspend
serumfre
media
plate
cultur
vessel
coat
matrix
compris
recombin
human
collagen
fibronectin
laminin
gibco
minut
nonadher
cell
collect
cultur
supernat
via
centrifug
remain
adher
cell
separ
harvest
via
scrape
cell
fraction
lyse
qiagen
buffer
rlt
store
later
rna
extract
adher
nonadher
fraction
ident
cultur
use
viabil
test
via
trypan
blue
data
repres
lymphocyt
popul
obtain
three
healthi
donor
assay
triplic
